Development of acute autoimmune encephalomyelitis in mice: factors regulating the effector phase of the disease.
The development of acute experimental autoimmune encephalomyelitis (EAE) in mice is potentiated by the use of Bordetella pertussis vaccine as an adjuvant. Histamine sensitizing factor (HSF) extracted from B. pertussis is the active adjuvant agent and causes a mild increase in cerebrovascular permeability. During the development of EAE, there is an additional increase in vascular permeability of the brain and spinal cord. The adjuvant action of B. pertussis HSF does not appear to mimic a generalized beta-adrenergic blockade, since the course of EAE is not potentiated by adrenalectomy. The cerebrovascular permeability changes observed in EAE are probably mediated by vasoactive amines, since the expression of EAE can be blocked by vasoactive amine antagonists.
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000311:Adrenal Glands / Q000502:physiology; D000818:Animals; D001886:Bordetella pertussis / Q000276:immunology; D001921:Brain / Q000098:blood supply; D002199:Capillary Permeability / Q000187:drug effects*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000503:physiopathology*; D005260:Female; D008297:Male; D008784:Methysergide / Q000494:pharmacology; D051379:Mice; D010293:Pargyline / Q000494:pharmacology; D037342:Pertussis Toxin; D011738:Pyrilamine / Q000494:pharmacology; D010566:Virulence Factors, Bordetella
D000276:Adjuvants, Immunologic; D010566:Virulence Factors, Bordetella; D010293:Pargyline; D037342:Pertussis Toxin; D011738:Pyrilamine; D008784:Methysergide